Open AccessP1455: FIRST‐IN‐HUMAN TRIAL OF CB‐010, A CRISPR‐EDITED ALLOGENEIC ANTI‐CD19 CAR ‐T CELL THERAPY WITH A PD‐1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON‐HODGKIN LYMPHOMA (ANTLER STUDY)
Author(s) -
Nastoupil L. J.,
O'Brien S.,
Holmes H. E.,
Dsouza L.,
Hart D.,
Matsuda E.,
SatterfieldLedbetter T.,
Skoble J.,
Garner E.,
Bryan M.,
Kanner S.,
Li E.,
Thomas C. T.,
Essell J.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000848676.15840.df
Subject(s) - tolerability , medicine , oncology , cd19 , cytokine release syndrome , adverse effect , immunotherapy , cancer , chimeric antigen receptor , peripheral blood